The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...

The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying ...

Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...

Salmonella can cause serious and potentially fatal infections in young children, the frail or elderly, and others with ...

U.S. Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the ...

By Sriparna Roy and Sneha S K (Reuters) -The U.S. Food and Drug Administration said on Monday it has appointed George ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing seven FDA-approved drugs.

Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...

For consumers, the FDA and Upper Crust Bakery LP advised that bread with affected lot numbers should not be consumed but instead discarded or returned to the point of purchase for a refund. Health ...